A comparative clinical study of PF-06410293, a candidate adalimumab biosimilar, and adalimumab reference product (Humira®) in the treatment of active rheumatoid arthritis

Overview of attention for article published in Arthritis Research & Therapy, August 2018

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
Among the highest-scoring outputs from this source (#20 of 3,381)
High Attention Score compared to outputs of the same age (97th percentile)
High Attention Score compared to outputs of the same age and source (98th percentile)

So far, Altmetric has seen 17 news stories from 17 outlets.

The Food and Drug Administration (FDA) has approved Abrilada (adalimumab-afzb; Pfizer), a biosimilar to Humira (adalimumab…

November 18, 2019 - Pfizer Inc. (NYSE: PFE) today announced the United States (U.S.) Food and Drug Administration (FDA) has…

The Food and Drug Administration has cleared adalimumab-afzb (Abrilada) as the fifth approved Humira biosimilar and the 25th…

NEW YORK --(BUSINESS WIRE)-- Pfizer Inc. (NYSE: PFE) today announced the United States (U.S.) Food and Drug Administration (FDA…

This page shows the most recent news stories that mention this research output.

Click here to find out how to access more activity, including 13 additional news stories.